Clinical Trial Update: Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study [Phase 1]

View source ↗

Summary

Phase 1 outpatient study evaluating a sublingual formulation of dexmedetomidine hydrochloride (BXCL501) for alcohol use disorder and post-traumatic stress disor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• Post-traumatic Stress Disorder

Drugs mentioned

• BXCL501 (dexmedetomidine)

Snippet

Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD) | Phase 1 | Status: RECRUITING